Verseon is a technology-based drug discovery company founded in 2002. Our proprietary, computer-driven drug discovery platform uses computational chemistry, physics-based molecular modeling, and optimization embedded into a comprehensive in-house laboratory workflow to identify novel drug candidates faster and more inexpensively than conventional methods.
We use our platform to establish a diversified pipeline across multiple disease areas, and currently have drug programs in anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.